ranibizumab   Click here for help

GtoPdb Ligand ID: 6779

Synonyms: Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2
Approved drug
ranibizumab is an approved drug (FDA (2006), EMA (2007))
Compound class: Antibody
Comment: Ranibizumab is a Fab fragment of a monoclonal antibody designed to target vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody derivative are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals that ranibizumab sequences are claimed in patent WO1998045331 (clone Y0317) [2], with an expected affinity similar to clone Y0313-1. It is the Fab fragment of bevacizumab.

Biosimilars:
Patent protection for originator ranibizumab is expected to expire in 2020 in the US and 2022 in the EU, and biosimilar development is well underway [4].
Intas Pharmaceuticals launched their Razumab biosimilar in India in 2015. Formycon/Santo Holdings' FYB201 has completed Phase 3 clinical evaluation in direct comparision with the originator product (NCT02611778) and Samsung Bioepis' SB11 has entered Phase 3 evaluation in trial NCT03150589. Results from these Phase 3 trials have yet to be disclosed.
Click here for help
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2006), EMA (2007))
International Nonproprietary Names Click here for help
INN number INN
8313 ranibizumab
Synonyms Click here for help
Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 84
Reactome Drug Reactome logo R-ALL-9679464
Reactome Reaction Reactome logo R-HSA-9679477
Other databases
GtoPdb PubChem SID 178103385
PubChem SID 178103385
Search PubMed clinical trials ranibizumab
Search PubMed titles ranibizumab
Search PubMed titles/abstracts ranibizumab
Wikipedia Ranibizumab